We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Parker-Hannifin
PH
$135B
| $103M | 0.19% |
605,542
+38,993
| +7% | +$6.72M |
|
52
Linde
LIN
$226B
| $101M | 0.19% |
501,007
+32,457
| +7% | +$6.07M |
|
53
S&P Global
SPGI
$119B
| $94.5M | 0.18% |
415,057
+26,602
| +7% | +$5.81M |
|
54
Intercontinental Exchange
ICE
$84.1B
| $91.5M | 0.17% |
1,064,829
+69,097
| +7% | +$5.64M |
|
|
55
Alcon
ALC
$33.9B
| $86.5M | 0.16% |
+1,393,674
| New | +$81.8M |
|
56
El Paso Energy Capital Trust I
EP.PRC
$223M
| $81.2M | 0.15% |
1,102,249
| – | – |
|
|
57
Bank of America Series L
BAC.PRL
$3.98B
| $79.7M | 0.15% |
1,161,940
-29,680
| -2% | -$39.5M |
|
58
Ingevity
NGVT
$2.66B
| $74.8M | 0.14% |
710,810
+28,742
| +4% | +$2.89M |
|
59
BioMarin Pharmaceuticals
BMRN
$11.9B
| $73.1M | 0.14% |
853,075
-4,481
| -0.5% | -$383K |
|
60
Tyler Technologies
TYL
$12.5B
| $71.2M | 0.13% |
329,430
-5,203
| -2% | -$1.13M |
|
61
Pool Corp
POOL
$7.31B
| $68.6M | 0.13% |
358,991
+55,137
| +18% | +$9.95M |
|
62
Insulet
PODD
$9.66B
| $66.9M | 0.13% |
560,663
+15,264
| +3% | +$1.56M |
|
63
Goldman Sachs
GS
$301B
| $65.8M | 0.12% |
321,372
+20,780
| +7% | +$4.11M |
|
64
Grand Canyon Education
LOPE
$3.88B
| $62.1M | 0.12% |
530,781
+6,734
| +1% | +$804K |
|
65
Generac Holdings
GNRC
$12.5B
| $61.7M | 0.12% |
888,753
-1,612
| -0.2% | -$94.2K |
|
66
NVR
NVR
$16.8B
| $58M | 0.11% |
17,213
+1,085
| +7% | +$3.48M |
|
67
WEX
WEX
$6.46B
| $55.6M | 0.1% |
267,314
-42,277
| -14% | -$8.51M |
|
68
Enviri
NVRI
$630M
| $55.6M | 0.1% |
2,027,235
+89,365
| +5% | +$2.18M |
|
69
Hexcel
HXL
$7.79B
| $53.9M | 0.1% |
666,057
+8,168
| +1% | +$594K |
|
|
WMGI
70
DELISTED
Wright Medical Group Inc
WMGI
| $53.7M | 0.1% |
1,801,146
+23,955
| +1% | +$731K |
|
71
Albany International
AIN
$1.74B
| $52.5M | 0.1% |
632,656
+165,213
| +35% | +$12.4M |
|
72
SiteOne Landscape Supply
SITE
$4.3B
| $52.2M | 0.1% |
753,471
+172,004
| +30% | +$11.1M |
|
73
LyondellBasell Industries
LYB
$19.8B
| $52.1M | 0.1% |
604,630
+14,898
| +3% | +$1.27M |
|
74
Bright Horizons
BFAM
$3.89B
| $51.9M | 0.1% |
343,681
+2,403
| +0.7% | +$322K |
|
|
PRAH
75
DELISTED
PRA Health Sciences, Inc.
PRAH
| $51.8M | 0.1% |
522,848
+37,335
| +8% | +$3.56M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.